These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 2886896)
41. Sucralfate and other non-antisecretory agents in the treatment of peptic ulcer disease. May B Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():113-6. PubMed ID: 2657280 [TBL] [Abstract][Full Text] [Related]
42. [Innovations in the treatment of gastroduodenal ulcers]. Bernier JJ Presse Med; 1983 May; 12(21):1355-8. PubMed ID: 6304676 [TBL] [Abstract][Full Text] [Related]
43. Health and economic aspects of peptic ulcer disease. Jensen DM Am J Med; 1984 Nov; 77(5B):8-14. PubMed ID: 6150640 [TBL] [Abstract][Full Text] [Related]
44. [A comparative evaluation of the efficacy of sucralfate and H2-histamine blockaders in treating peptic ulcer]. Ivashkin VT; Tkachenko EI; Grinevich VB; Sultanov VK; Inozemtsev SA Ter Arkh; 1989; 61(8):59-62. PubMed ID: 2573963 [TBL] [Abstract][Full Text] [Related]
45. [Pharmacologic treatment of ulcers]. Honorato Pérez J; Azanza Perea JR; Cuena Boy R Rev Med Univ Navarra; 1984 Jun; 28(2):53-8. PubMed ID: 6149611 [No Abstract] [Full Text] [Related]
46. Current guidelines on stress ulcer prophylaxis. Tryba M; Cook D Drugs; 1997 Oct; 54(4):581-96. PubMed ID: 9339962 [TBL] [Abstract][Full Text] [Related]
47. [Prevention of duodenal ulcer recurrence. A new prospect]. Soulé JC Presse Med; 1991 Mar; 20(10):465-70. PubMed ID: 1673786 [TBL] [Abstract][Full Text] [Related]
48. Bismuth is better. Tytgat GN Scand J Gastroenterol Suppl; 1988; 155():16-7. PubMed ID: 3244996 [TBL] [Abstract][Full Text] [Related]
52. Influence of initial therapy on outcome of peptic ulcer. Korman MG Scand J Gastroenterol Suppl; 1995; 208():21-3. PubMed ID: 7777799 [TBL] [Abstract][Full Text] [Related]
53. Medical therapy of peptic ulcer disease. McQuaid KR; Isenberg JI Surg Clin North Am; 1992 Apr; 72(2):285-316. PubMed ID: 1347960 [TBL] [Abstract][Full Text] [Related]
54. Newer drugs in the treatment of peptic ulcer. Tandon BN Trop Gastroenterol; 1985; 6(4):188-92. PubMed ID: 3913076 [No Abstract] [Full Text] [Related]
55. [Advances in ulcer therapy]. Domschke W Fortschr Med; 1983 Apr; 101(13):575-82. PubMed ID: 6133827 [No Abstract] [Full Text] [Related]
56. Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Tytgat GN; Lamers CB; Hameeteman W; Jansen JM; Wilson JA Aliment Pharmacol Ther; 1987 Feb; 1(1):31-8. PubMed ID: 2908747 [TBL] [Abstract][Full Text] [Related]
57. Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials. Dobrilla G; Vallaperta P; Amplatz S Gut; 1988 Feb; 29(2):181-7. PubMed ID: 2894337 [TBL] [Abstract][Full Text] [Related]
58. NSAID-induced gastrointestinal damage. A critical review of prophylaxis and therapy. McCarthy DM J Clin Gastroenterol; 1990; 12 Suppl 2():S13-20. PubMed ID: 1978842 [TBL] [Abstract][Full Text] [Related]
59. The pharmacology of peptic ulcer disease. Ippoliti A; Peterson W Clin Gastroenterol; 1979 Jan; 8(1):53-67. PubMed ID: 369747 [No Abstract] [Full Text] [Related]
60. Colloidal bismuth in the treatment of duodenal ulceration: the benefit for the patient. Miller JP Scand J Gastroenterol Suppl; 1989; 157():16-20; discussion 21-2. PubMed ID: 2568684 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]